Purpose: Tumor Treating Fields (TTFields) disrupt tumor cells while they are undergoing mitosis. In patients, transducer arrays are applied to scalp or body surface for treatment of glioblastomas, mesothelioma, or other systemic malignancies. Dermatologic complications are thought to be related to hydrogel, which is applied between the electrodes and scalp or skin surface to facilitate electric field penetration. But the high intensity of TTFields on these surfaces may also be a contributing factor.Methods and Materials: Magnetic resonance imaging data sets from 7 glioblastoma patients and attenuation-corrected positron emission tomography–computed tomography data sets from 3 non-small cell lung carcinoma and 2 ovarian carcinoma patients were used to fully segment various anatomic structures. A 3-dimensional finite element mesh model was generated and then solved for the distribution of applied electric fields, rate of energy deposition, and current density at the gross tumor volumes (GTVs) and clinical target volumes (CTVs). Electric field-volume histograms, specific absorption rate–volume histograms, and current density-volume histograms were generated, by which plan quality metrics were used to evaluate relative differences in field coverage between models at various hydrogel conductivities.Results: TTFields coverage at the GTV or CTV increased up to 0.5 S/m for head and 1.0 S/m for thorax and pelvis models, and no additional increase was observed after these saturation points. The scalp and skin hotspots also increased accordingly. Although the scalp hotspots increased by +4.2%, +7.5%, and +3.2% in E5%, SAR5%, and CD5%, the skin hotspots increased by as much as +21.7%, +51.3%, and +41.0%, respectively.Conclusion: TTFields delivery for the treatment of cancer can be modulated by the conductivity of the hydrogel at the transducer-scalp or transducer-skin interface. Optimizing this aspect of TTFields delivery may increase tumor control while minimizing toxicity at the scalp or skin.